204192-41-6

Upstream product

• 204193-43-1 8-(2-(hydroxymethyl)phenyl)-1,4-dioxaspiro[4.5]decan-8-ol 
• 76-05-1 trifluoroacetic acid 
• 78988-21-3 3H-dispiro[2-benzofuran-1,1'-cyclohexane-4',2''-[1,3]dioxolane] 
• 1252607-62-7 [2-(1,4-dioxa-spiro[4.5]dec-7-en-8-yl)-phenyl]-methanol 
• 18982-54-2 o-bromobenzyl alcohol 
• 69225-59-8 3,3-dimethyl-1,5-dioxaspiro[5.5]undecan-9-one 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 6630-33-7 ortho-bromobenzaldehyde 

Downstream Products

• 204192-38-1 2-fluoro-4-(trans)-(4-(3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl)piperazin-1-yl)benzonitrile 

Relevant academic research and scientific papers

Desymmetrizing Isomerization of Alkene via Thiazolinyl Iminoquinoline Cobalt Catalysis

We report a cobalt-catalyzed desymmetrizing isomerization of exo-cyclic alkenes to generate chiral 1-methylcyclohexene derivatives with good yields and enantioselectivities. A novel chiral thiazolinyl iminoquinoline ligand and its cobalt complex were desi

INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE

The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders

4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

2-(Bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation

Compounds disclosed herein are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

Spirocyclic dopamine receptor subtype ligands

This invention relates to novel, pharmaceutically active compounds of formula (I) wherein a, b and R1through R6are as defined in the specification These compounds exhibit central dopaminergic activity and are useful in the treatment

Synthesis of a spiro[cyclohex-1,1′-isobenzofuranyl] dopamine receptor antagonist

Two syntheses of the novel CNS agent, 2-fluoro-4-(trans)-(4-(3'H-spiro[cyclohex-l,1'-isobenzofuran]-4-yl)-piperazin-1- yl)benzonitrile, 1, are presented. The first relied on a reductive alkylation with low regioselectivity (1:1) but was sufficient for the